دورية أكاديمية

BCR-ABL V280G mutation, potential role in imatinib resistance: First case report

التفاصيل البيبلوغرافية
العنوان: BCR-ABL V280G mutation, potential role in imatinib resistance: First case report
المؤلفون: Azevedo, A.P., Reichert, A., Afonso, C., Alberca, M.D., Tavares, P., Lima, F.
المساهمون: NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), Centre for Toxicogenomics and Human Health (ToxOmics)
سنة النشر: 2017
المجموعة: Repositório da Universidade Nova de Lisboa (UNL)
مصطلحات موضوعية: BCR-ABL, CML, Imatinib, Mutation, Nilotinib, alpha interferon, BCR ABL protein, glycine, hydroxyurea, valine, aged, amino acid substitution, Article, BCR ABL gene, case report, chromosome 22, chromosome 9, chronic myeloid leukemia, clinical article, disease course, drug dose escalation, drug withdrawal, EUTOS score, female, gene, gene mutation, gene sequence, Hasford score, human, leukoderma
الوصف: Export Date: 28 December 2017 Correspondence Address: Azevedo, A.P.; Department of Clinical Pathology, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Estrada do Forte do Alto do Duque, Portugal; email: anpazevedo@gmail.com Chemicals/CAS: glycine, 56-40-6, 6000-43-7, 6000-44-8; hydroxyurea, 127-07-1; imatinib, 152459-95-5, 220127-57-1; nilotinib, 641571-10-0; valine, 7004-03-7, 72-18-4 References: Radich, J.P., Shah, N.P., Mauro, M.J., Integrating current treatment options for TKIresistant chronic myeloid leukemia (2014) Clin Adv Hematol Oncol, 12 (11), pp. 3-17; Savona, M.R., Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia (2014) J Community Support Oncol, 12, pp. 171-178; Kantarjian, H.M., Cortes, J., La Rosée, P., Hochhaus, A., Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase (2010) Cancer, 116, pp. 1419-1430; Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A., Griffin, J.D., Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007) Nat Rev Cancer, 7, pp. 345-356; Nicolini, F.E., Corm, S., Lê, Q.H., Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP) (2006) Leukemia, 20, pp. 1061-1066; Soverini, S., Colarossi, S., Gnani, A., Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia (2006) Clin Cancer Res, 12, pp. 7374-7379; Sokal, J.E., Cox, E.B., Baccarani, M., Prognostic discrimination in “good-risk” chronic granulocytic leukemia (1984) Blood, 63, pp. 789-799; Hasford, J., Pfirrmann, M., Hehlmann, R., A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 1179-5549
العلاقة: PURE: 3409376; PURE UUID: f17d9eee-10b8-4735-944e-b6cc0466eff3; RIS: urn:36A8B04607F1A98BEFB272DE462E7119; PubMed: 28469513; PubMedCentral: PMC5395261; Scopus: 85034627995; WOS: 000399413600001; https://www.scopus.com/inward/record.uri?eid=2-s2.0-85034627995&doi=10.1177%2f1179554917702870&partnerID=40&md5=2f9e733c9917a0a3235f85279d0de323Test; https://doi.org/10.1177/1179554917702870Test
DOI: 10.1177/1179554917702870
الإتاحة: https://doi.org/10.1177/1179554917702870Test
حقوق: openAccess
رقم الانضمام: edsbas.7C344909
قاعدة البيانات: BASE
الوصف
تدمد:11795549
DOI:10.1177/1179554917702870